{"entity":{"type":"insider","cik":"0001470885","url":"/insider/0001470885","json_url":"/insider/0001470885.json","name":"Booth Mark D","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":8,"n_filings":5,"first":"2012-06-29","last":"2015-03-02","span_basis":"filed_date"},"name_variants":[{"name":"Booth Mark D","source":"filing","n_filings":5,"first_seen":"2012-06-29","last_seen":"2015-03-02"}],"transactions":[{"id":8916877,"accession":"0001181431-15-003650","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-15-003650","line_url":"/filing/0001181431-15-003650#line-2","is_derivative":false,"issuer_cik":"0001382911","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001382911","owner_cik":"0001470885","owner_name":"Booth Mark D","owner_display_name":"Booth Mark D","owner_url":"/insider/0001470885","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":50000.0,"shares_display":"50,000","price_per_share":5.684,"price_display":"5.68","price_state":"stated","total_value":284200.0,"total_display":"284,200.00","total_whole":"284,200","shares_owned_after":3810.0,"shares_owned_after_display":"3,810","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-02-26","filed_date":"2015-03-02","scope":"insider"},{"id":4340038,"accession":"0001181431-13-041739","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001181431-13-041739","line_url":"/filing/0001181431-13-041739","is_derivative":false,"issuer_cik":"0001382911","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001382911","owner_cik":"0001470885","owner_name":"Booth Mark D","owner_display_name":"Booth Mark D","owner_url":"/insider/0001470885","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":64767.0,"shares_display":"64,767","price_per_share":7.551426652461902,"price_display":"7.55","price_state":"stated","total_value":489083.25,"total_display":"489,083.25","total_whole":"489,083","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-07-26","filed_date":"2013-07-29","scope":"insider","n_lines":3},{"id":5107834,"accession":"0001181431-13-016465","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-13-016465","line_url":"/filing/0001181431-13-016465#line-2","is_derivative":false,"issuer_cik":"0001382911","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001382911","owner_cik":"0001470885","owner_name":"Booth Mark D","owner_display_name":"Booth Mark D","owner_url":"/insider/0001470885","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27685.0,"shares_display":"27,685","price_per_share":6.67,"price_display":"6.67","price_state":"stated","total_value":184658.95,"total_display":"184,658.95","total_whole":"184,659","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-03-11","filed_date":"2013-03-12","scope":"insider"},{"id":4815265,"accession":"0001181431-13-003836","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001181431-13-003836","line_url":"/filing/0001181431-13-003836","is_derivative":false,"issuer_cik":"0001382911","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001382911","owner_cik":"0001470885","owner_name":"Booth Mark D","owner_display_name":"Booth Mark D","owner_url":"/insider/0001470885","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22315.0,"shares_display":"22,315","price_per_share":6.670022406453058,"price_display":"6.67","price_state":"stated","total_value":148841.55,"total_display":"148,841.55","total_whole":"148,842","shares_owned_after":100.0,"shares_owned_after_display":"100","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-01-15","filed_date":"2013-01-18","scope":"insider","n_lines":2},{"id":3439203,"accession":"0001181431-12-038583","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001181431-12-038583","line_url":"/filing/0001181431-12-038583#line-2","is_derivative":false,"issuer_cik":"0001382911","issuer_name":"Orexigen Therapeutics, Inc.","issuer_ticker":"OREX","issuer_name_source":null,"issuer_url":"/issuer/0001382911","owner_cik":"0001470885","owner_name":"Booth Mark D","owner_display_name":"Booth Mark D","owner_url":"/insider/0001470885","role":"Officer (Chief Commercial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Commercial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Commercial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":103309.0,"shares_display":"103,309","price_per_share":5.66,"price_display":"5.66","price_state":"stated","total_value":584728.94,"total_display":"584,728.94","total_whole":"584,729","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2012-06-28","filed_date":"2012-06-29","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":8,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":8,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":8},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001382911","name":"Orexigen Therapeutics, Inc.","url":"/issuer/0001382911","role":"Officer (Chief Commercial Officer)","n_filings":5,"first_seen":"2012-06-29","last_seen":"2015-03-02"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001470885","retrieved_at":"2026-08-23T13:03:34+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}